Antibacterial and Antiviral Complex
A laminated structure of a base material, carbon material, and antibacterial/antiviral agent addresses the limitations of existing agents by enhancing surface interaction and retention, achieving superior antibacterial and antiviral performance with excellent color tone for diverse applications.
Patent Information
- Application Number
- JP2023505508
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-09-16
- Filing Date
- 2022-03-04
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2042-03-04
AI Technical Summary
Existing antibacterial and antiviral agents lack sufficient performance, are easily washed away from surfaces, and have limited applications due to coloration, necessitating a technology that enhances surface interaction and retention while maintaining excellent color tone.
A laminated structure of a base material, carbon material, and antibacterial/antiviral agent, where the carbon material interacts strongly with the antibacterial/antiviral agent to improve retention and performance, using graphene oxide or reduced graphene oxide, and compounds such as quaternary nitrogen cations, metal elements, or halogen elements for enhanced antibacterial and antiviral properties.
The laminated structure achieves high antibacterial and antiviral performance with strong retention on surfaces, effectively inhibiting bacterial and viral growth, and provides excellent color tone, suitable for various applications including sanitary products, biomaterials, and electronic equipment.
Smart Images

Figure 0007591795000006 
Figure 0007591795000007 
Figure 0007591795000008
Abstract
Description
[Technical field]
[0001] The present invention relates to an antibacterial and antiviral complex, a manufacturing method thereof, an antibacterial and antiviral coating method, and a set for manufacturing the antibacterial and antiviral complex. More specifically, the present invention relates to an antibacterial and antiviral complex useful for sanitary products, biomaterials, cleaning agents, cosmetics, paints, resins, wood preservatives, cement admixtures, water treatment agents, industrial water, paper pulp, plastics, fibers, food additives, medical devices, optical devices, modules, electronic products, etc., a manufacturing method thereof, an antibacterial and antiviral coating method, and a set for manufacturing the antibacterial and antiviral complex. [Background technology]
[0002] Infectious diseases caused by bacteria, viruses, etc., are a threat to human life, and therefore there is a global demand for measures against bacteria, viruses, etc. In recent years, in Japan, due to consumer awareness of cleanliness, various products that have been treated with antibacterial agents are commercially available in various fields, not only in the medical and hygiene fields. Well-known antibacterial and antiviral agents used in antibacterial and antiviral processing include, for example, organic agents that have quaternary ammonium bases, and inorganic agents that contain metal ions such as silver, copper, and zinc.
[0003] In recent years, biological applications of carbon materials have been studied, and antibacterial and antiviral agents using carbon materials have been developed. Regarding antibacterial agents containing carbon materials, Patent Document 1 discloses a dental coating composition used for applying to tooth surfaces to provide sustained antibacterial properties, the composition being composed of a dispersion of graphene oxide particles dispersed in a mixed solution of water and N-methyl-2-pyrrolidone, the mixed solution of water and N-methyl-2-pyrrolidone having a concentration of N-methyl-2-pyrrolidone in the range of 0.1 to 20% by mass. Patent Document 2 discloses an antibacterial composition characterized by containing a carbon material having a G band in a Raman spectrum and a zinc component. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] JP 2016-074636 A [Patent Document 2] JP 2020-070278 A Summary of the Invention [Problem to be solved by the invention]
[0005] As described above, various antibacterial and antiviral agents have been disclosed in the past, but the antibacterial agent disclosed in Patent Document 1 does not have sufficient antibacterial activity, and the antibacterial composition disclosed in Patent Document 2 has limited applications due to coloring derived from carbon materials, so there has been a demand for an agent with excellent antibacterial activity and excellent color tone. In addition, commercially available water-soluble antibacterial and antiviral agents are water-based and can be easily used on living organisms such as the human body, and have sufficient antibacterial and antiviral activity, but because they are water-soluble, it is difficult to keep them on the surface of a living organism for a long period of time. Therefore, there has been a demand for a technology to keep such water-soluble antibacterial and antiviral agents on the surface.
[0006] The present invention has been made in consideration of the above-mentioned current situation, and has an object to provide an antibacterial and antiviral composite that has a strong interaction between the antibacterial and antiviral agent and the surface of a substrate, exhibits excellent antibacterial and antiviral properties, and also has an excellent color tone. [Means for solving the problem]
[0007] The inventors conducted extensive research into antibacterial and antiviral materials and found that by laminating a carbon material and an antibacterial and antiviral agent in this order onto a substrate, a strong interaction is achieved between the antibacterial and antiviral agent and the substrate surface, resulting in excellent antibacterial and antiviral properties and excellent color tone. They then came to the conclusion that the above-mentioned problems could be solved beautifully, and completed the present invention.
[0008] That is, the present invention relates to an antibacterial and antiviral composite having a structure in which a substrate, a carbon material, and an antibacterial and antiviral agent are layered in this order.
[0009] The carbon material is preferably graphene oxide or reduced graphene oxide.
[0010] The antibacterial and antiviral agent preferably has at least one selected from the group consisting of a quaternary nitrogen cation-containing group, a primary to tertiary amino group, a metal element and a halogen element.
[0011] The quaternary nitrogen cation-containing group is preferably at least one selected from the group consisting of a quaternary ammonium group, an iminium group, and a pyridinium group.
[0012] The above antibacterial and antiviral agent preferably has a cationic structure.
[0013] The substrate is preferably at least one selected from the group consisting of metal, glass, fiber, collagen, cellulose, resin, ceramic, enamel, and dentin.
[0014] The antibacterial and antiviral composite preferably has an average number of layers of the carbon material of 10 or less.
[0015] The present invention also relates to a method for providing an antibacterial and antiviral coating on a substrate, the method including the steps of forming a film of a carbon material on the substrate and combining an antibacterial and antiviral agent with the carbon material on the substrate obtained in the film-forming step.
[0016] In the film-forming step, it is preferable to use a carbon material composition having a carbon material concentration of 0.001 to 10 mass %.
[0017] The present invention further provides a method for producing an antibacterial and antiviral composite, the method including the steps of forming a film of a carbon material on a substrate, and conjugating an antibacterial and antiviral agent with the carbon material on the substrate obtained in the film-forming step.
[0018] In the film-forming step, it is preferable to use a carbon material composition having a carbon material concentration of 0.001 to 10 mass %.
[0019] The present invention further relates to a set for producing an antibacterial and antiviral composite, the set being a set for producing an antibacterial and antiviral composite having a carbon material or a carbon material composition and an antibacterial and antiviral agent or an antibacterial and antiviral agent composition. Effect of the Invention
[0020] The antibacterial and antiviral complex of the present invention has the above-mentioned configuration and has high antibacterial and antiviral performance and antibacterial and antiviral retention performance, as well as excellent color tone, and can therefore be suitably used in sanitary products, biomaterials, cleaning agents, cosmetics, paints, resins, wood preservatives, cement admixtures, water treatment agents, industrial water, paper pulp, plastics, fibers, food additives, medical devices, optical devices, modules, electronic products, etc. [Brief description of the drawings]
[0021] [Figure 1] 1 is a graph showing the results of antibacterial evaluation (1) against S. mutans of the antibacterial and antiviral complex (1) of Example 1, comparative antibacterial and antiviral complexes (1) and (2) of Comparative Examples 1 and 2, and a control. [Diagram 2] 1 is a graph showing the results of antibacterial evaluation (1) against S. mutans of the antibacterial and antiviral complex (2) of Example 2, the comparative antibacterial and antiviral complexes (1) and (3) of Comparative Examples 1 and 3, and a control. [Diagram 3] 1 is a graph showing the results of antibacterial evaluation (2) against A. naeslundii of the antibacterial and antiviral complex (3) of Example 3, the comparative antibacterial and antiviral complexes (4) and (5) of Comparative Examples 4 and 5, and a control. [Figure 4] 1 is a chart showing the Raman spectrum of the antibacterial and antiviral complex (4) of Example 4. [Diagram 5]1 is a chart showing the Raman spectrum of the antibacterial and antiviral complex (5) of Example 5. [Figure 6] 1 is a chart showing the Raman spectrum of the antibacterial and antiviral complex (6) of Example 6. [Figure 7] 1 is a chart showing the Raman spectrum of the comparative antibacterial and antiviral complex (6) of Comparative Example 6. [Figure 8] 1 is a chart showing the Raman spectrum of the comparative antibacterial and antiviral complex (7) of Comparative Example 7. [Figure 9] 1 is a chart showing the Raman spectrum of the comparative antibacterial and antiviral complex (8) of Comparative Example 8. [Figure 10] 1 is a chart showing the Raman spectrum of the comparative antibacterial and antiviral complex (9) of Comparative Example 9. [Figure 11] 1 is a chart showing the Raman spectrum of a quartz substrate that was fired as a control. [Figure 12] 1 is a chart showing C1s spectra by XPS analysis of the antibacterial and antiviral complexes (4) to (6) of Examples 4 to 6 and the comparative antibacterial and antiviral complex (6) of Comparative Example 6. [Figure 13] 1 is a chart showing C1s spectra by XPS analysis of comparative antibacterial and antiviral complexes (7) to (9) of Comparative Examples 7 to 9 and a fired quartz substrate as a control. [Figure 14] 1 is a chart showing N1s spectra by XPS analysis of the antibacterial and antiviral complexes (4) to (6) of Examples 4 to 6 and the comparative antibacterial and antiviral complex (6) of Comparative Example 6. [Figure 15] 1 is a chart showing N1s spectra by XPS analysis of comparative antibacterial and antiviral complexes (7) to (9) of Comparative Examples 7 to 9 and a fired quartz substrate as a control. [Figure 16] 1 is an SEM photograph (magnification: 1000 times) of the antibacterial and antiviral complex (4) of Example 4. [Figure 17] 1 is an SEM photograph (magnification: 1000 times) of the antibacterial and antiviral complex (5) of Example 5. [Figure 18] 1 is an SEM photograph (magnification: 1000 times) of the antibacterial and antiviral complex (6) of Example 6. [Figure 19] 1 is an SEM photograph (magnification: 1000 times) of the comparative antibacterial and antiviral complex (6) of Comparative Example 6. [Figure 20] 1 is a chart showing the Raman spectrum of the antibacterial and antiviral complex (7) of Example 7. [Figure 21] 1 is a chart showing the Raman spectrum of the antibacterial and antiviral complex (8) of Example 8. [Figure 22] 1 is a chart showing the Raman spectrum of the comparative antibacterial and antiviral complex (10) of Comparative Example 10. [Diagram 23] 1 is a chart showing the Raman spectrum of the comparative antibacterial and antiviral complex (11) of Comparative Example 11. [Figure 24] 1 shows an example of microscopic observation (one example) and a graph showing the results of antibacterial evaluation (3) against A. naeslundii of the antibacterial and antiviral complex (7) of Example 7 and the comparative antibacterial and antiviral complexes (10) and (11) of Comparative Examples 10 and 11. [Diagram 25] 1 is a graph showing the results of the antibacterial evaluation against S. mutans (1) and the antibacterial evaluation against A. naeslundii (5) of the antibacterial and antiviral complex of Example 9 (9), the comparative antibacterial and antiviral complexes of Comparative Examples 12 and 13 (12) and (13), and the control. [Figure 26] 1 is a graph showing the results of antibacterial evaluation (5) of the antibacterial and antiviral complexes (10) to (15) of Examples 10 to 15 against A. naeslundii. [Figure 27] 1 is a graph showing the results of the antibacterial evaluation (4) against Escherichia coli of the antibacterial and antiviral complex (3) of Example 3, the comparative antibacterial and antiviral complexes (4) and (5) of Comparative Examples 4 and 5, and a control. [Figure 28]1 is a graph showing the results of the antiviral evaluation (1) against coronavirus (SARS-CoV-2) of the antibacterial and antiviral complex (2) of Example 2, the comparative antibacterial and antiviral complexes (1) and (3) of Comparative Examples 1 and 3, and a control. [Figure 29] 1 is a graph showing the results of the antibacterial evaluation (3) against A. naeslundii of the antibacterial and antiviral complex (18) of Example 18, and the comparative antibacterial and antiviral complexes (1) and (16) of Comparative Examples 1 and 14. [Diagram 30] 1 is a graph showing the results of antibacterial evaluation (1) against S. mutans of the antibacterial and antiviral complex (19) of Example 19, the comparative antibacterial and antiviral complexes (3) and (15) of Comparative Examples 3 and 15, and a control. [Diagram 31] 1 is a graph showing the results of antibacterial evaluation (2) against A. naeslundii of the antibacterial and antiviral complex (19) of Example 19, the comparative antibacterial and antiviral complexes (3) and (15) of Comparative Examples 3 and 15, and a control. [Diagram 32] 1 is a graph showing the results of antibacterial evaluation (1) against S. mutans for the antibacterial and antiviral complex (20) of Example 20, the comparative antibacterial and antiviral complexes (1) and (16) of Comparative Examples 1 and 16, and a control. [Diagram 33] 1 is a graph showing the results of antibacterial evaluation (2) against A. naeslundii of the antibacterial and antiviral complex (20) of Example 20, the comparative antibacterial and antiviral complexes (1) and (16) of Comparative Examples 1 and 16, and a control. [Diagram 34] 1 is a graph showing the results of antibacterial evaluation (2) of the antibacterial and antiviral complexes of Example 21 (2W1, 2W3, 2W7, 2W30, 2W30+) and a control against A. naeslundii. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] A preferred embodiment of the present invention will be specifically described below, but the present invention is not limited to the following description, and can be appropriately modified and applied within the scope of the present invention. A combination of two or more of the individual preferred embodiments of the present invention described below also falls within the preferred embodiment of the present invention. In this specification, the expression "antibacterial / antiviral" means having either antibacterial or antiviral properties, or having both antibacterial and antiviral properties. In addition, what is described as antibacterial may or may not have antiviral properties, and what is described as antiviral may or may not have antibacterial properties.
[0023] <Antibacterial and antiviral complex> The antibacterial and antiviral composite of the present invention has a structure in which a substrate, a carbon material, and an antibacterial and antiviral agent are laminated in this order. In the above antibacterial and antiviral composite, the carbon material on the substrate interacts with the substrate and the antibacterial and antiviral agent, so that the antibacterial and antiviral agent is sufficiently held on the substrate, thereby enabling the composite to exhibit excellent antibacterial and antiviral properties and antibacterial and antiviral retention. Furthermore, the antibacterial and antiviral composite of the present invention can also exhibit deodorizing and deodorizing effects by suppressing the proliferation of bacteria and the like that cause odors.
[0024] The antibacterial and antiviral complex of the present invention has antibacterial and antiviral properties, and antibacterial and antiviral properties refer to the properties of bactericidal (killing microorganisms and inactivating viruses), bacteriostasis (suppressing the growth of microorganisms and viruses), sterilization, disinfection, bacteriostatic, disinfecting, antiseptic, antifungal, etc. Antibacterial and antiviral targets include bacteria, fungi, and viruses, specifically Actinobacteria such as Actinomyces naeslundii and Actinomyces viscosus; Firmicutes such as Streptococcus mutans, Staphylococcus aureus, and Enterococcus faecalis; Proteobacteria such as Aggregatibacter actinomycetemcomitans, Escherichia coli, and Salmonella enterica; Bacteroidetes such as Porphyromonas gingivalis, Prevotella intermedia, and Tannerella forsythia; Fusobacteria such as Fusobacterium nucleatum; Chlamydiae such as Chlamydia trachomatis; Spirochaetes such as Treponem denticola; Ascomycota such as Candida albicans; RNA viruses such as influenza viruses, SARS-CoV-2, and human immunodeficiency virus type 1; and herpes simplex. Examples of such viruses include DNA viruses such as viruses, hepatitis B virus, and adenovirus.
[0025] The antibacterial and antiviral composite of the present invention is not particularly limited as long as it has a structure in which the substrate, the carbon material, and the antibacterial and antiviral agent are laminated in this order, but the ratio of the antibacterial and antiviral agent to 100% by mass of the carbon material is preferably 0.01 to 100% by mass. This allows the antibacterial and antiviral properties and antibacterial and antiviral retention properties to be more fully exhibited. It is more preferably 0.05 to 10% by mass, and even more preferably 0.1 to 5% by mass. The proportion of the antibacterial and antiviral agent can be calculated by XPS from the difference in the amount of C and elements (e.g. nitrogen, metals, etc.) present only in the antibacterial and antiviral agent between a sample in which the carbon material is only formed into a film and a sample in which it is made into a composite.
[0026] The antibacterial and antiviral composite of the present invention has a carbon material content of 0.1 to 100 mg / m relative to the surface area of the substrate. 2 More preferably, it is 0.5 to 50 mg / m 2 and more preferably 1 to 10 mg / m 2 It is. The content of the carbon material can be calculated by AFM measurement.
[0027] The carbon material is not particularly limited as long as it interacts with the antibacterial and antiviral agent, but it is preferable that it has carbon bonded to oxygen (O). When the carbon material of the present invention has carbon bonded to oxygen (O), the ratio of the number of carbon atoms to the number of oxygen atoms (C / O) is preferably 0.5 to 20. The ratio is more preferably 1 or more, and even more preferably 1.2 or more. Moreover, the ratio is more preferably 10 or less, even more preferably 6 or less, even more preferably 4 or less, and particularly preferably 3 or less. The ratio of the number of carbon atoms to the number of oxygen atoms can be confirmed by the ratio of the total peak area in the O1s region to the total peak area in the C1s region obtained by XPS measurement.
[0028] The carbon material of the present invention is more preferably one having a graphene skeleton. The carbon material having the graphene skeleton is sp 2The carbon material has carbon (C) bonded by a bond, and the carbon is arranged in a plane. More preferably, the carbon is bonded to oxygen (O), and even more preferably, the graphene oxide is a graphene in which oxygen is bonded to the carbon of the graphene. The graphene oxide may be reduced graphene oxide obtained by partially reducing the graphene in which oxygen is bonded to the carbon, and for example, the graphene oxide may be reduced by being combined with an antibacterial / antiviral agent, or may be reduced by a treatment during and / or after the film formation. The embodiment in which the carbon material is graphene oxide or reduced graphene oxide is one of the preferred embodiments of the present invention. The carbon material has a structure in which carbon is arranged in a plane as described above, and the effective area that can interact with the substrate is increased, and the carbon material has carbon bonded to oxygen (O), which allows for more sufficient interaction with the substrate surface and the functional group of the antibacterial / antiviral agent, thereby allowing the effect of the present invention to be more fully exhibited.
[0029] When the carbon material of the present invention has carbon bonded to oxygen (O), the method of producing the carbon material is generally a method of reacting graphite with a strong oxidizing agent in an acid solvent, and the Hummers method using sulfuric acid and potassium permanganate as oxidizing agents can be used. Other methods include the Brodie method using nitric acid and potassium chlorate, and the Staudenmaier method using sulfuric acid, nitric acid, and potassium chlorate as oxidizing agents. When the oxidation method in the Hummers method is adopted, a method of adding permanganate to a mixed liquid containing graphite and sulfuric acid may be used. The carbon material thus obtained is usually purified by a method such as filtration, decantation, centrifugation, liquid separation extraction, and water washing. The purification may be performed in air or in an inert gas atmosphere such as nitrogen, helium, or argon. In addition, the purification may be performed under any of pressurized conditions, normal pressure conditions, and reduced pressure conditions. By performing ultrasonic treatment or homogenizer treatment after purification, it is possible to peel off each graphene oxide layer and reduce the number of layers. In addition, the dispersion containing the carbon material may be neutralized with a base such as potassium hydroxide or sodium hydroxide before or after purification.
[0030] The carbon material is laminated on a substrate, and the number of layers of the carbon material is not particularly limited, but the average number of layers is preferably 10 or less. This further improves adhesion to the substrate, and more sufficiently suppresses coloration of the substrate. The average number of layers of the carbon material is more preferably 8 or less, even more preferably 5 or less, particularly preferably 3 or less, and most preferably 1. The number of layers of the carbon material can be measured by a scanning electron microscope or an atomic force microscope.
[0031] The carbon material laminated on the substrate preferably has an absorbance of 0.05 or less at a wavelength of 660 nm measured with an ultraviolet-visible spectrophotometer, more preferably an absorbance of 0.01 or less.
[0032] The substrate in the antibacterial and antiviral composite of the present invention is not particularly limited as long as it can laminate a carbon material, but is preferably at least one selected from the group consisting of metal, glass, fiber, collagen, cellulose, resin, ceramic, enamel, cementum and dentin, and more preferably glass, fiber or dentin.
[0033] The antibacterial and antiviral agent in the antibacterial and antiviral composite of the present invention is not particularly limited as long as it exhibits antibacterial and antiviral performance and interacts with the carbon material, but is preferably water-soluble. Daily necessities and the like are often washed with water, and when they are treated with a water-soluble antibacterial and antiviral agent, they may be washed away and the antibacterial and antiviral properties may not be fully exhibited. In contrast, in the present invention, the substrate, the carbon material, and the antibacterial and antiviral agent are laminated in this order to form a composite, and the strong interaction between the carbon material and the antibacterial and antiviral agent sufficiently suppresses the antibacterial and antiviral agent from being washed away even if it is water-soluble, so that when the antibacterial and antiviral agent is water-soluble, the technical significance of the present invention can be more effectively exhibited. As described in Patent Documents 1 and 2, graphene oxide can also exhibit antibacterial and antiviral performance, but the antibacterial and antiviral agent in the present invention is other than the above-mentioned carbon material.
[0034] More preferably, the antibacterial and antiviral agent has at least one selected from the group consisting of a quaternary nitrogen cation-containing group, a primary to tertiary amino group, a metal element, and a halogen element. The quaternary nitrogen cation-containing group is not particularly limited as long as it has a quaternary nitrogen cation, and examples thereof include a quaternary ammonium group, an iminium group, and a pyridinium group. More preferably, the antibacterial and antiviral agent has a quaternary nitrogen cation group, a metal element, or a halogen element, and most preferably a quaternary nitrogen cation-containing group. The most preferred quaternary nitrogen cation-containing group is an ammonium group.
[0035] More preferably, the antibacterial and antiviral agent has a cationic structure such as a quaternary ammonium group, a primary to tertiary amino group, an iminium group, or a metal ion. This further strengthens the interaction with the carbon material, and the antibacterial action lasts for a longer period of time. Examples of the cationic structure include those represented by the following formulae (1) to (4);
[0036] [ka]
[0037] (In the formula, R 1 , R 2 R are the same or different and each represents a hydrocarbon group having 1 to 30 carbon atoms which may have a hydrogen atom or a hetero atom. 3 , R 4 , R 5 R are the same or different and each represents a hydrocarbon group having 1 to 30 carbon atoms which may have a heteroatom. 1 , R 2 or R 3 , R 4 Or R 3 , R 4 , R 5 Two of X may be bonded to form a ring structure. - represents an anion. A group represented by the following formula (I) or an ion of a metal element described later is preferred. The antibacterial and antiviral agent may have one cationic structure or two or more cationic structures.
[0038] The hydrocarbon group having 1 to 30 carbon atoms is not particularly limited, but may be an alkyl group, an alkenyl group, an alkynyl group, an aryl group, etc., and a carbon atom in the hydrocarbon group may be substituted with a heteroatom. The heteroatom may be an oxygen atom, a sulfur atom, a nitrogen atom, a phosphorus atom, etc. An oxygen atom is preferable, and an embodiment in which the hydrocarbon group has an ether group such as an oxyethylene group or an oxypropylene group is also one of the preferred embodiments of the present invention.
[0039] The hydrocarbon group having 1 to 30 carbon atoms preferably has 1 to 25 carbon atoms, and more preferably 1 to 20 carbon atoms.
[0040] Above X - is an anion, and examples thereof include, but are not limited to, halide ions such as chloride ion, bromide ion, and iodine ion; alkyl sulfate ions such as methyl sulfate ion; and ions of organic acids such as acetate ion.
[0041] The antibacterial and antiviral agents having a quaternary ammonium group and a primary to tertiary amino group may be low molecular weight compounds or high molecular weight compounds. Examples of the high molecular weight compounds include those represented by the following formulae (5) to (8);
[0042] [ka]
[0043] (In formulas (5) and (6), R 1 , R 2 are the same or different and each represents a hydrocarbon group having 1 to 30 carbon atoms which may have a hydrogen atom or a hetero atom. 3 ~R 5 are the same or different and each represents a hydrocarbon group having 1 to 30 carbon atoms which may have a heteroatom. Z represents a hydrogen atom or a methyl group. Y represents a divalent linking group. X- represents an anion. m and n are the same or different and each is an integer of 1 to 3. Examples of the polymer include a polymer having a structural unit derived from a monomer represented by the following formula:
[0044] Specific examples of the monomers represented by the above formulas (5) to (8) include N,N-dialkylamino group-containing (meth)acrylates such as N,N-dimethylaminoethyl (meth)acrylate, N,N-diethylaminoethyl (meth)acrylate, N,N-dimethylaminopropyl (meth)acrylate, and N,N-diethylaminopropyl (meth)acrylate, as well as monomers obtained by adding a quaternizing agent to the above monomers, or neutralized products thereof with an acid such as hydrochloric acid or acetic acid; N,N-dimethylaminoethyl (meth)acrylamide, N,N-diethylaminoethyl (meth)acrylamide, N,N-dimethylaminopropyl (meth)acrylamide, and N,N-diethylaminopropyl (meth)acrylamide, as N,N-dialkylamino group-containing (meth)acrylamides, as well as monomers obtained by adding a quaternizing agent to the above monomers, or neutralized products thereof with an acid such as hydrochloric acid or acetic acid; monomethylaminoethyl (meth)acrylate, monoethylaminoethyl (meth)acrylate, Monoalkylamino group-containing (meth)acrylates such as monomethylaminopropyl (meth)acrylate, monoethylaminopropyl (meth)acrylate, 2-(tert-butylamino)ethyl (meth)acrylate, and their neutralization products with acids such as hydrochloric acid and acetic acid; monoalkylamino group-containing (meth)acrylamides such as monomethylaminoethyl (meth)acrylamide, monoethylaminoethyl (meth)acrylamide, monomethylaminopropyl (meth)acrylamide, monoethylaminopropyl (meth)acrylamide, and their neutralization products with acids such as hydrochloric acid and acetic acid; esters of (meth)acrylic acid and alkanolamines such as 2-aminoethyl (meth)acrylate, and their neutralization products with acids such as hydrochloric acid and acetic acid; N,N-diallylmethylamines such as diallyldimethylammonium chloride and their monomers with a quaternizing agent, or their neutralization products with acids such as hydrochloric acid and acetic acid; allylamines and their neutralization products with acids such as hydrochloric acid and acetic acid;Examples of the monomer include an addition reaction product of an unsaturated monomer having a cyclic ether-containing group having 2 to 8 carbon atoms, such as 1-allyloxy-3-dibutylamino-2-ol or 1-allyloxy-3-diethanolamino-2-ol, with an amine compound having 1 to 24 carbon atoms, and a monomer obtained by adding a quaternizing agent thereto, or a neutralization product thereof with an acid such as hydrochloric acid or acetic acid;
[0045] Examples of the low molecular weight compound having a cationic group include compounds having a quaternary ammonium group, such as benzalkonium chloride, cetylpyridinium chloride, benzethonium chloride, methylbenzethonium chloride, cetrimonium, dophanium chloride, tetraethylammonium bromide, didecyldimethylammonium chloride, domiphen bromide, stearyltrimethylammonium bromide, cetyltrimethylammonium bromide, and lauryltrimethylammonium bromide; compounds having a primary to tertiary amino group, such as alkylamines such as methylamine, dialkylamines such as dimethylamine, trialkylamines such as trimethylamine, ethanolamine, diethanolamine, triethanolamine, polyethyleneimine, and alkyldiaminoethylglycine (and their proton adducts, for example, hydrochlorides).
[0046] As the cationic group-containing compound, those represented by the following formulae (9) to (11) are more preferable:
[0047] [ka]
[0048] (In the formula, R 3 , R 4 , R 5 , R 6 R are the same or different and represent a hydrocarbon group having 1 to 30 carbon atoms which may have a hydrogen atom or a hetero atom. 3 , R 4 , R 5 , R 6 Two of R may be bonded to form a ring structure. 7represents an alkyl group having 1 to 24 carbon atoms; p represents a number from 0 to 3; and X represents an anion. Above R 7 The number of carbon atoms in the alkyl group is preferably 4 to 18. p is preferably 0 to 2.
[0049] More preferably, the compound having the above cationic group is a compound having a quaternary ammonium group, and more preferably, benzalkonium chloride, cetylpyridinium chloride, or benzethonium chloride.
[0050] Examples of the metal element in the antibacterial and antiviral agent include silver, copper, zinc, cobalt, nickel, palladium, cadmium, tin, platinum, gold, mercury, etc. Preferred are silver, copper and zinc.
[0051] The antibacterial and antiviral agents containing the above-mentioned metal elements are not particularly limited, and examples thereof include nitrates, sulfates, nitrites, phosphates, chlorides, fluorides, bromides, iodides, acetates, borates, chlorates, bromates, iodates, perchlorates, perbromates, periodates, permanganates, thiocyanates, tetrafluoroborates, and hexafluorophosphates of the above-mentioned metal elements.
[0052] The antibacterial and antiviral agents having a halogen element are not particularly limited, and may be, for example, any agent having a halogen element such as fluorine, chlorine, bromine, or iodine. Specific examples of the antibacterial and antiviral agents having a halogen element include iodine, hydrogen iodide, povidone iodine, sodium fluoride, tin fluoride, sodium bis monofluorophosphate, (1,4-bromoacetoxy)-2-butene, 2-bromo-2-nitropropane-1,3-diol, bis(trichloro)sulfone, 5-oxy-3,4-dichloro-1,2-dithiol, 1-[(diiodomethyl)sulfonyl]-4-methylbenzene, 3-iodo-2-propargyl butylcarbamate, N,N,N'-trimethyl-N'-fluorodimethylthio-N'-phenyl sulfide, 2,3,5,6-tetrachloroisophthalonitrile, 3,4,5-tribromosalicylanilide, and 2,2-dibromo-1-indanone.
[0053] The antibacterial and antiviral agent having at least one selected from the group consisting of a quaternary ammonium group, a primary to tertiary amino group, an iminium group, a metal element, and a halogen element may contain a plurality of the above groups or elements, and for example, the antibacterial and antiviral agent having a quaternary ammonium group may have a halogen element.
[0054] The antibacterial and antiviral composite of the present invention has the above-mentioned constitution, has excellent antibacterial and antiviral properties, and is almost colorless, and therefore can be used in a wide range of applications, specifically, biomaterial applications used for tissue regeneration such as bones and skin, artificial teeth, etc.; detergent applications such as laundry detergents, fabric softeners, household detergents, dishwashing detergents, and hard surface cleaners; cosmetic applications such as shampoos, rinses, lotions, milky lotions, creams, sunscreens, foundations, and eye makeup products, and antiperspirants; industrial applications such as paints, wood preservatives, cement admixtures, and industrial water (papermaking process water in papermaking processes, and various industrial cooling water and cleaning water); sanitary products such as masks, eye patches, bandages, bandages, and gauze; medical instruments; textile products such as clothing; food additives, and electronic equipment applications such as solar cell modules, organic element devices, and heat shielding films. In particular, the antibacterial and antiviral composite of the present invention can be used more preferably in biomaterial applications.
[0055] <Method of manufacturing antibacterial and antiviral composite> The method of manufacturing the antibacterial and antiviral composite of the present invention is not particularly limited, but it is preferable to manufacture the antibacterial and antiviral composite by carrying out a step of forming a film of a carbon material on a substrate and a step of conjugating an antibacterial and antiviral agent to the carbon material on the substrate obtained in the film-forming step. The present invention is a method of manufacturing an antibacterial and antiviral composite, which is also a method of manufacturing an antibacterial and antiviral composite including a step of forming a film of a carbon material on a substrate (hereinafter also referred to as a film-forming step) and a step of conjugating an antibacterial and antiviral agent to the carbon material on the substrate obtained in the film-forming step (hereinafter also referred to as a conjugation step).
[0056] The film-forming step is not particularly limited as long as it is possible to form a film of a carbon material on a substrate, and can be performed by a method of immersing a substrate in a composition containing a carbon material (hereinafter also referred to as a carbon material composition) or a method of applying a composition containing a carbon material to a substrate.
[0057] The concentration of the carbon material in the carbon material composition used in the film-forming step is preferably 0.001 to 10% by mass. This further improves the coverage of the substrate. The concentration is more preferably 0.005 to 5% by mass, and even more preferably 0.1 to 2% by mass.
[0058] The carbon material composition is not particularly limited as long as it contains a carbon material, but may contain other components such as a solvent. The solvent is not particularly limited as long as it disperses the carbon material, and polar solvents such as water; amides such as N-methyl-2-pyrrolidone, N,N'-dimethylformamide, and N,N'-dimethylacetamide; and alcohols such as methanol, ethanol, and isopropyl alcohol are preferred. By including a polar solvent in the carbon material-containing composition, the dispersibility of the carbon material is further improved, and a more uniform film can be formed. Water is more preferred.
[0059] Other components that may be contained in the carbon material composition are not particularly limited, and examples thereof include a surfactant, etc. This further improves the dispersion stability of the carbon material composition.
[0060] The method for producing the antibacterial and antiviral composite may include a step of washing the substrate after the film-forming step. This allows the carbon material that has not been formed into a film to be removed more sufficiently. The concentration of the carbon material used to more sufficiently suppress coloration is preferably within the above-mentioned range, but even if the concentration is high, it is possible to make the substrate as colorless as possible by removing excess carbon material that has not interacted with the outermost surface of the substrate. In this case, regardless of the concentration (amount) of the carbon material used, the amount of carbon material that ultimately remains on the substrate surface is the amount of carbon material that can interact with the outermost surface of the substrate. The effect of the present invention is fully exhibited even if the carbon material is only on the outermost surface. In addition, by selectively removing multiple layers of carbon material through the washing process, a thin film of about a single layer to about 10 layers is likely to remain. Furthermore, it is also preferable to repeat the film-forming step and the washing step multiple times. This allows the thickness and coverage of the carbon material film to be changed arbitrarily.
[0061] The above-mentioned composite step is not particularly limited as long as it is possible to composite the antibacterial and antiviral agent with the carbon material on the substrate obtained in the film-forming step, and can be performed by a method of immersing the substrate after film formation in a composition containing the antibacterial and antiviral agent (hereinafter also referred to as the antibacterial and antiviral agent composition) or a method of applying the antibacterial and antiviral agent composition to the substrate after film formation, for example.
[0062] The concentration of the antibacterial and antiviral agent in the antibacterial and antiviral agent composition used in the above-mentioned composite step is preferably 0.001 to 100% by mass. This allows the antibacterial and antiviral agent to be composited with the carbon material more efficiently. The concentration is more preferably 0.01 to 50% by mass, and even more preferably 0.1 to 10% by mass.
[0063] The antibacterial and antiviral agent composition is not particularly limited as long as it contains an antibacterial and antiviral agent, but may contain other components such as a solvent. Examples of the solvent include those mentioned above, and water is preferred.
[0064] The method for producing the antibacterial and antiviral composite may include a step of washing the substrate after the composite step. This allows the non-complexed antibacterial and antiviral agent to be removed more thoroughly. The composite step and removal step may be repeated multiple times. This allows the carbon material and the antibacterial and antiviral agent to be effectively composited.
[0065] <Antibacterial and antiviral coating method> The present invention also provides a method for applying an antibacterial and antiviral coating to a substrate, the method comprising the steps of forming a film of a carbon material on the substrate and compounding an antibacterial and antiviral agent with the carbon material on the substrate obtained in the film-forming step. The film-forming step and compounding step are the same as the film-forming step and compounding step in the method for producing the antibacterial and antiviral composite. The antibacterial and antiviral coating method may also include the above-mentioned cleaning step.
[0066] <Antibacterial and antiviral complex manufacturing set> The present invention is a set for manufacturing an antibacterial and antiviral composite, and the set is also a set for manufacturing an antibacterial and antiviral composite having a carbon material or a carbon material composition and an antibacterial and antiviral agent or an antibacterial and antiviral agent composition. It is preferable that the set for manufacturing the antibacterial and antiviral composite has a carbon material composition and an antibacterial and antiviral agent composition. Specific examples and preferred examples of the carbon material and the antibacterial and antiviral agent in the set are as described in the antibacterial and antiviral composite, and the carbon material composition and the antibacterial and antiviral agent composition are preferably the same as those used in the manufacturing method of the antibacterial and antiviral composite and the antibacterial and antiviral coating method.
Examples
[0067] The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to only these examples. Unless otherwise specified, "parts" means "parts by mass" and "%" means "% by mass".
[0068] Measurements of various physical properties were carried out by the following methods. <Measurement of Raman spectrum> Raman spectroscopic analysis was carried out using the following apparatus and conditions. Measurement apparatus: Micro Raman (JASCO NRS-3100) Measurement conditions: Using a 532 nm laser, 20x objective lens, CCD capture time 1 second, integration 32 times (resolution = 4 cm -1 )
[0069] <Analysis by X-ray photoelectron spectroscopy (XPS)> AXIS-NOVA X-ray source and output of Shimadzu Kratos Co., Ltd., AlKα - 100W, pass energy 40 eV, neutralization gun ON
[0070] <SEM observation> SEM observation was carried out using a scanning electron microscope (JSM-7600F, manufactured by JEOL Ltd.) at an accelerating electron energy of 5.0 keV, and a secondary electron image was observed.
[0071] <Measurement using an ultraviolet-visible spectrophotometer> The transmittance of the quartz substrate was set to 100%, and the absorbance of each sample at 660 nm was measured using an ultraviolet-visible spectrophotometer (Shimadzu Corporation, UV-3100).
[0072] <Antibacterial evaluation (1)> Each sample was prepared in a 48-well plate, and Streptococcus mutans (ATCC 35668) (1.0 × 10 7 Each was inoculated with a suspension consisting of 0.1% CFU / mL of sucrose and medium (Brain Heart Infusion Medium (Eiken Chemical Co., Ltd.) supplemented with 0.1% gramicidin (Fujifilm Wako Pure Chemical Co., Ltd.), 0.1% bacitracin (Fujifilm Wako Pure Chemical Co., Ltd.), and 1% sucrose (Fujifilm Wako Pure Chemical Co., Ltd.)) and cultured anaerobically at 37°C for 24 hours, after which the turbidity of the medium was measured at 590 nm using a visible light photometer (Funakoshi Co., Ltd., CO7500). The lower the turbidity, the higher the antibacterial activity. A similar test was also performed on a control without any sample.
[0073] <Antibacterial evaluation (2)> Each sample was placed in a 48-well plate and incubated with Actinomyces naeslundii (ATCC 27039) (2.0 × 10 6 A suspension consisting of 100% sucrose (CFU / mL) and medium (Actinomyces medium (Becton Dickinson)) was inoculated and cultured anaerobically at 37°C for 24 hours, after which the turbidity of the medium was measured at 590 nm using a visible light photometer (Funakoshi CO7500). The lower the turbidity, the higher the antibacterial activity. A similar test was also performed on untreated gauze as a control.
[0074] <Antibacterial evaluation (3)> Each sample was placed in a 48-well plate and incubated with Actinomyces naeslundii (ATCC 27039) (1.0 × 10 7A suspension consisting of 1000 CFU / mL of 1000 ng / mL lysine and medium (Actinomyces medium) was inoculated and cultured anaerobically at 37°C for 24 hours. The cultured samples were washed with phosphate-buffered saline, stained for live or dead (live bacteria are green, dead bacteria are red) using a LIVE / DEAD BacLight Bacterial Viability Kit (Thermo Fisher Scientific), and observed under a fluorescence microscope. The green and red fluorescence intensities were measured using image processing software (ImageJ) (live bacteria are shown in white and dead bacteria are shown in black in the figures).
[0075] <Antibacterial evaluation (4)> The test was conducted in the same manner as in the antibacterial evaluation (2), except that the bacterial species was changed to Escherichia coli (ATCC 25922) and the medium was changed to brain heart infusion medium.
[0076] <Antibacterial evaluation (5)> The test was performed in the same manner as in the antibacterial evaluation (1), except that the bacterial species was changed to Actinomyces naeslundii (ATCC 2703) and the medium was changed to Actinomyces medium.
[0077] <Antiviral Evaluation (1)> The virus solution (SARS-CoV-2 JPN / TY / WK-521 strain) was diluted with DMEM medium containing 2% FCS to 10^6 TCID 50 / mL. The virus solution was added to each sample in an amount of 0.25 mL, sealed, and left to stand at room temperature. After 24 hours, the samples were removed and the virus infectivity was measured. The virus infectivity was measured using TMPRSS2-expressing VeroE6 cells at 50% Tissue Culture Infectious Dose (TCID 50 ) was analyzed.
[0078] <Preparation Example 1> Preparation of graphene oxide dispersion (1) A graphene oxide (hereinafter also referred to as GO) dispersion was synthesized by the following process. 15 g of graphite (Z-25 manufactured by Ito Graphite Co., Ltd.) and 640 g of sulfuric acid (manufactured by Fujifilm Wako Pure Chemical Co., Ltd.) were placed in a reaction vessel in advance, and 45 g of potassium permanganate (manufactured by Fujifilm Wako Pure Chemical Co., Ltd.) was added while adjusting the temperature to 30 ° C. After the addition, the temperature was raised to 35 ° C. for 30 minutes and the reaction was allowed to proceed for 2 hours. After the reaction, the reaction solution was added with 1070 ml of water and 42 ml of 30% hydrogen peroxide solution (manufactured by Fujifilm Wako Pure Chemical Co., Ltd.) to stop the reaction. The obtained reaction solution was purified by repeatedly removing the supernatant and redispersing with ion-exchanged water by leaving it to settle. After purification, a peeling operation was performed using a homogenizer to prepare GO dispersion (1).
[0079] Example 1: Preparation of antibacterial and antiviral complex (1) The GO dispersion was adjusted to a concentration of 0.1%, and 0.1 mL was dropped onto a 48-well plate. At this time, the GO dispersion completely covered the bottom of the plate. It was allowed to dry at room temperature, and then water was vigorously sprayed onto the GO film using a dental water gun (Morita Seisakusho Co., Ltd.) to wash it, remove excess GO, and dry it. A 0.1% aqueous solution of cetylpyridinium chloride (CPC, Tokyo Chemical Industry Co., Ltd.) was dropped onto the 48-well plate with the GO film. After impregnation, it was washed three times with distilled water to remove excess CPC, and then dried to prepare the antibacterial and antiviral complex (1).
[0080] Example 2: Preparation of antibacterial and antiviral complex (2) An antibacterial and antiviral complex (2) was prepared in the same manner as in Example 1, except that CPC was changed to benzalkonium chloride (BAC, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.).
[0081] Comparative Example 1: Preparation of Comparative Antibacterial and Antiviral Complex (1) A comparative antibacterial and antiviral complex (1) was prepared in the same manner as in Example 1, except that CPC was not used.
[0082] Comparative Example 2: Preparation of comparative antibacterial and antiviral complex (2) A comparative antibacterial and antiviral complex (2) was prepared in the same manner as in Example 1, except that GO was not used.
[0083] Comparative Example 3: Preparation of comparative antibacterial and antiviral complex (3) A comparative antibacterial and antiviral complex (3) was prepared in the same manner as in Comparative Example 2, except that CPC was changed to BAC.
[0084] Example 3: Preparation of antibacterial and antiviral complex (3) A piece of folded gauze (manufactured by Nichiei Co., Ltd.) cut into a 1 cm square was immersed in a 0.001% GO dispersion for 10 seconds, washed three times with distilled water, and then immersed in a 0.1% CPC dispersion for 10 seconds, washed three times with distilled water, and dried to prepare the antibacterial and antiviral complex (3).
[0085] Comparative Example 4: Preparation of comparative antibacterial and antiviral complex (4) A comparative antibacterial and antiviral complex (4) was prepared in the same manner as in Example 3, except that CPC was not used.
[0086] Comparative Example 5: Preparation of Comparative Antibacterial and Antiviral Complex (5) A comparative antibacterial and antiviral complex (5) was prepared in the same manner as in Example 3, except that GO was not used.
[0087] Example 4: Preparation of antibacterial and antiviral complex (4) As a pretreatment, a fused quartz polished plate (20 mm x 20 mm x 1 mmt) manufactured by AS ONE was heated at 700 °C for 2 hours in an air atmosphere to burn off the organic matter on the surface. Using this quartz substrate, the GO dispersion synthesized in Preparation Example 1 was adjusted to a concentration of 0.1%, and 0.4 ml was cast onto the quartz substrate. At this time, the GO dispersion completely covered the quartz substrate. It was dried under vacuum at room temperature, and then ion-exchanged water was vigorously sprayed onto the GO film to wash it and remove excess GO. After vacuum drying again, CPC was made into a 0.1% aqueous solution, and the substrate was immersed in the solution for 10 seconds. After impregnation, excess CPC was removed by washing with water, and the substrate was dried in vacuum to obtain antibacterial and antiviral complex (4). The absorbance was less than 0.01. This antibacterial and antiviral complex (4) was left together with the substrate in ion-exchanged water for one month to obtain antibacterial and antiviral complex (4W). XPS analysis showed that the CPC contained in the antibacterial / antiviral complex (4W) remained at 80% compared to the antibacterial / antiviral complex (4).
[0088] Example 5: Preparation of antibacterial and antiviral complex (5) An antibacterial / antiviral complex (5) was prepared in the same manner as in Example 4, except that CPC was replaced with BAC. The absorbance was less than 0.01. This antibacterial / antiviral complex (5) was left together with the substrate in ion-exchanged water for one month to obtain an antibacterial / antiviral complex (5W). XPS analysis showed that 100% of the BAC contained in the antibacterial / antiviral complex (5) remained, compared to the antibacterial / antiviral complex (5).
[0089] Example 6: Preparation of antibacterial and antiviral complex (6) An antibacterial / antiviral complex (6) was prepared in the same manner as in Example 4, except that CPC was changed to benzethonium chloride (BZC, manufactured by Tokyo Chemical Industry Co., Ltd.). The absorbance was less than 0.01. This antibacterial / antiviral complex (6) was left together with the substrate in ion-exchanged water for one month to obtain an antibacterial / antiviral complex (6W). XPS analysis revealed that 90% of the BZC contained in the antibacterial / antiviral complex (6) remained compared to the antibacterial / antiviral complex (6).
[0090] Comparative Example 6: Preparation of comparative antibacterial and antiviral complex (6) The product from Example 4 was prepared after removing excess GO and vacuum drying (only GO, no antibacterial agent). The absorbance was less than 0.01. This comparative antibacterial / antiviral complex (6) was left together with the substrate in ion-exchanged water for one month to obtain comparative antibacterial / antiviral complex (6W). XPS analysis showed that 100% of the GO contained in the comparative antibacterial / antiviral complex (6) remained, compared to the comparative antibacterial / antiviral complex (6).
[0091] Comparative Example 7: Preparation of comparative antibacterial and antiviral complex (7) After the organic matter was burned off in Example 4, the GO film formation process was omitted, and the substrate was immersed in a 0.1% CPC aqueous solution for 10 seconds. After the immersion, excess CPC was removed by washing with water, and the substrate was dried in a vacuum (only CPC, no GO). The absorbance was less than 0.01.
[0092] Comparative Example 8: Preparation of comparative antibacterial and antiviral complex (8) Except for changing CPC to BAC, a comparative antibacterial and antiviral complex (8) was prepared in the same manner as in Comparative Example 7. The absorbance was less than 0.01.
[0093] Comparative Example 9: Preparation of comparative antibacterial and antiviral complex (9) Except for changing CPC to BZC, a comparative antibacterial and antiviral complex (9) was prepared in the same manner as in Comparative Example 7. The absorbance was less than 0.01.
[0094] Example 7: Preparation of antibacterial and antiviral complex (7) A dentin chip with a thickness of 1 mm was cut from a human tooth root using a diamond disk, and after ultrasonic cleaning in distilled water for 5 minutes, it was immersed in a 0.01% GO dispersion for 10 seconds, and air-dried at room temperature without washing. It was then immersed in 0.1% CPC for 10 seconds, washed three times with distilled water, and dried to prepare the antibacterial and antiviral complex (7).
[0095] Example 8: Preparation of antibacterial and antiviral complex (8) An antibacterial and antiviral complex (8) was prepared in the same manner as in Example 7, except that CPC was changed to benzalkonium chloride (BAC).
[0096] Comparative Example 10: Preparation of comparative antibacterial and antiviral complex (10) A comparative antibacterial and antiviral complex (10) was prepared in the same manner as in Example 7, except that CPC was not used.
[0097] Comparative Example 11: Preparation of comparative antibacterial and antiviral complex (11) A comparative antibacterial and antiviral complex (11) was prepared in the same manner as in Example 7, except that GO was not used.
[0098] Example 9: Preparation of antibacterial and antiviral complex (9) An antibacterial and antiviral complex (9) was prepared in the same manner as in Example 1, except that CPC was changed to benzethonium chloride (BZC).
[0099] Comparative Example 12: Preparation of comparative antibacterial and antiviral complex (12) A comparative antibacterial and antiviral complex (12) was prepared in the same manner as in Example 9, except that BZC was not used.
[0100] Comparative Example 13: Preparation of comparative antibacterial and antiviral complex (13) A comparative antibacterial and antiviral complex (13) was prepared in the same manner as in Example 9, except that GO was not used.
[0101] Example 10: Preparation of antibacterial and antiviral complex (10) An antibacterial and antiviral complex (10) was prepared in the same manner as in Example 1, except that the CPC concentration used was 1%.
[0102] Example 11: Preparation of antibacterial and antiviral complex (11) An antibacterial and antiviral complex (11) was prepared in the same manner as in Example 10, except that the CPC concentration used was 0.1%.
[0103] Example 12: Preparation of antibacterial and antiviral complex (12) An antibacterial and antiviral complex (12) was prepared in the same manner as in Example 10, except that the CPC concentration used was 0.01%.
[0104] Example 13: Preparation of antibacterial and antiviral complex (13) The antibacterial and antiviral complex (13) was prepared in the same manner as in Example 2, except that the BAC concentration used was 1%.
[0105] Example 14: Preparation of antibacterial and antiviral complex (14) An antibacterial / antiviral complex (14) was prepared in the same manner as in Example 13, except that the BAC concentration used was 0.1%.
[0106] Example 15: Preparation of antibacterial and antiviral complex (15) An antibacterial and antiviral complex (15) was prepared in the same manner as in Example 13, except that the BAC concentration used was 0.01%.
[0107] Example 16: Preparation of antibacterial and antiviral complex (16) An antibacterial and antiviral complex (16) was prepared in the same manner as in Example 4, except that a 0.1% zinc acetate aqueous solution (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) was used instead of the 0.1% CPC aqueous solution. This antibacterial / antiviral complex (16) was left together with the substrate in ion-exchanged water for one month to obtain antibacterial / antiviral complex (16W). XPS analysis showed that 50% of the zinc contained in the antibacterial / antiviral complex (16) remained.
[0108] Example 17: Preparation of antibacterial and antiviral complex (17) An antibacterial and antiviral complex (17) was prepared in the same manner as in Example 4, except that a 0.1% silver acetate aqueous solution (manufactured by Aldrich) was used instead of the 0.1% CPC aqueous solution. This antibacterial / antiviral complex (17) was left together with the substrate in ion-exchanged water for one month to obtain antibacterial / antiviral complex (17W). XPS analysis showed that 30% of the silver contained in the antibacterial / antiviral complex (17) remained.
[0109] Example 18: Preparation of antibacterial and antiviral complex (18) An antibacterial and antiviral complex (18) was prepared in the same manner as in Example 1, except that a 1% aqueous solution of alkyldiaminoethylglycine hydrochloride (ADAEG, Fujifilm Wako Pure Chemical Industries, Ltd.) was used instead of the 0.1% aqueous solution of CPC.
[0110] Comparative Example 14: Preparation of comparative antibacterial and antiviral complex (14) A comparative antibacterial and antiviral complex (14) was prepared in the same manner as in Example 18, except that GO was not used.
[0111] <Preparation Example 2> Preparation of neutralized graphene oxide dispersion (2) The GO dispersion (1) was neutralized with an aqueous potassium hydroxide solution to a pH of 6 to prepare neutralized GO dispersion (2).
[0112] Example 19: Preparation of antibacterial and antiviral complex (19) An antibacterial and antiviral composite (19) was prepared in the same manner as in Example 2, except that the neutralized GO dispersion (2) was used instead of the GO dispersion.
[0113] Comparative Example 15: Preparation of comparative antibacterial and antiviral complex (15) A comparative antibacterial / antiviral complex (15) was prepared in the same manner as in Example 19, except that BAC was not used.
[0114] Example 20: Preparation of antibacterial and antiviral complex (20) An antibacterial and antiviral complex (20) was prepared in the same manner as in Example 1, except that CPC was changed to Neosterin Green mouthwash (NEO, active ingredient: benzethonium chloride, manufactured by Nippon Dental Pharmaceuticals, diluted with water to 0.1% for use).
[0115] Comparative Example 16: Preparation of comparative antibacterial and antiviral complex (16) A comparative antibacterial and antiviral complex (16) was prepared in the same manner as in Example 20, except that GO was not used.
[0116] Example 21: Preparation of antibacterial and antiviral complexes (2W1, 2W3, 2W7, 2W30) Antibacterial and antiviral complex (2) was prepared in the same manner as in Example 2, and then stored in water for 1, 3, 7, and 30 days to obtain antibacterial and antiviral complexes (2W1, 2W3, 2W7, and 2W30), respectively. As described below, the antibacterial activity of the antibacterial and antiviral complex (2W30) had decreased, so 0.1 mL of a 0.1% aqueous solution of BAC was further dropped onto the plate. After impregnation, the plate was washed three times with distilled water to remove excess BAC, and then dried to prepare antibacterial and antiviral complex (2W30+).
[0117] The antibacterial and antiviral complexes (1) and (2) obtained in Examples 1 and 2, the comparative antibacterial and antiviral complexes (1) to (3) obtained in Comparative Examples 1 to 3, and an untreated medium as a control were subjected to an antibacterial activity evaluation (1) against S. mutans. The results are shown in Figures 1 and 2.
[0118] The antibacterial and antiviral complex (3) obtained in Example 3, the comparative antibacterial and antiviral complexes (4) and (5) obtained in Comparative Examples 4 and 5, and untreated gauze as a control were subjected to an antibacterial activity evaluation against A. naeslundii (2). The results are shown in Figure 3.
[0119] Raman spectrum, XPS analysis, and SEM measurement were performed on the antibacterial and antiviral complexes (4) to (6) obtained in Examples 4 to 6, the comparative antibacterial and antiviral complexes (6) to (9) obtained in Comparative Examples 6 to 9, and the fired quartz substrate as a control. The results are shown in Figures 4 to 19 and Table 1 (XPS analysis).
[0120] The Raman spectra and XPS analyses of the antibacterial and antiviral complexes (7) and (8) obtained in Examples 7 and 8, the comparative antibacterial and antiviral complexes (10) and (11) obtained in Comparative Examples 10 and 11, and the fired quartz substrate as a control are shown in Figures 20 to 23 and Table 2 (XPS analysis).
[0121] The antibacterial and antiviral complex (7) obtained in Example 7 and the comparative antibacterial and antiviral complexes (10) and (11) obtained in Comparative Examples 10 and 11 were subjected to an antibacterial activity evaluation against A. naeslundii (3). The results are shown in FIG.
[0122] The antibacterial and antiviral complex (9) obtained in Example 9, the comparative antibacterial and antiviral complexes (12) and (13) obtained in Comparative Examples 12 and 13, and an untreated medium as a control were subjected to an antibacterial activity evaluation (5) against S. mutans and A. naeslundii. The results are shown in FIG.
[0123] The antibacterial and antiviral complexes (10) to (15) obtained in Examples 10 to 15, and an untreated medium as a control, were subjected to an antibacterial activity evaluation against A. naeslundii (5). The results are shown in FIG. 26.
[0124] The antibacterial and antiviral complex (3) obtained in Example 3, the comparative antibacterial and antiviral complexes (4) and (5) of Comparative Examples 4 and 5, and an untreated medium as a control were subjected to an antibacterial activity evaluation against Escherichia coli (4). The results are shown in FIG.
[0125] The antiviral activity of the antibacterial and antiviral complex (2) obtained in Example 2, the comparative antibacterial and antiviral complexes (1) and (3) obtained in Comparative Examples 1 and 3, and an untreated medium as a control was evaluated against coronavirus (1). The results are shown in FIG.
[0126] The antibacterial and antiviral complex (18) obtained in Example 18 and the comparative antibacterial and antiviral complexes (1) and (14) obtained in Comparative Examples 1 and 14 were subjected to an antibacterial activity evaluation against A. naeslundii (2). The results are shown in FIG.
[0127] The antibacterial and antiviral complex (19) obtained in Example 19, the comparative antibacterial and antiviral complexes (3) and (15) obtained in Comparative Examples 3 and 15, and an untreated medium as a control were subjected to an antibacterial evaluation against S. mutans (1) and an antibacterial evaluation against A. naeslundii (2). The results are shown in Figures 30 and 31.
[0128] The antibacterial and antiviral complex (20) obtained in Example 20, the comparative antibacterial and antiviral complexes (1) and (16) obtained in Comparative Examples 1 and 16, and an untreated medium as a control were subjected to an antibacterial evaluation against S. mutans (1) and an antibacterial evaluation against A. naeslundii (2). The results are shown in Figures 32 and 33.
[0129] The antibacterial and antiviral complexes (2W1, 2W3, 2W7, 2W30, 2W30+) obtained in Example 21 and the control were subjected to antibacterial activity evaluation against A. naeslundii (2). The results are shown in FIG.
[0130] [Table 1]
[0131] [Table 2]
[0132] 1 to 3 and 24 to 33, it was revealed that the antibacterial and antiviral composite having a structure in which the substrate, the carbon material, and the antibacterial and antiviral agent are layered in this order has superior antibacterial and antiviral performance to the case of the carbon material alone, as compared to the case of the antibacterial and antiviral agent alone. In addition, as an index of antibacterial and antiviral properties (JIS, etc.), an antibacterial and antiviral rate of 99% or more after 24 hours is defined as having antibacterial and antiviral effects, and in the case of Example 2 of the present invention, an antibacterial property of 99.3% or more and an antiviral property of 99.7% or more were confirmed, so it can be said to have high antibacterial and antiviral effects.
[0133] Regarding the Raman spectra, in Figs. 4 to 7 and 20 to 23, -1 , 1350cm -1 A peak derived from GO was observed around 2800 cm in Figures 7 to 11 and 20 to 23, indicating that GO is contained in the antibacterial and antiviral complexes (4) to (8). It is also clear that GO is contained in the comparative antibacterial and antiviral complexes (7) and (10), which use only GO. -1 The peak observed nearby is due to instrument noise.
[0134] Regarding the XPS analysis, in Table 1, in Comparative Examples 7 to 9, C increased compared to the control due to the application of the antibacterial and antiviral agent, but N was not observed, and it can be seen that the amount of the antibacterial and antiviral agent was very small. In contrast, in Examples 4 to 6, both C and N increased compared to Comparative Example 6, which used only GO, and it can be seen that the antibacterial and antiviral agent was complexed. In other words, it can be seen that the antibacterial and antiviral agent was well retained due to the presence of GO. The arrows in Figures 12 and 13 indicate peaks derived from CO. In Table 2, in Examples 7, 8, and Comparative Examples 10 and 11, the ratios of C and N were taken and compared based on the amount of Ca derived from dentin, and it can be seen that the ratios of O and N in Examples 7 and 8 were increased compared to the control, indicating that GO and the antibacterial and antiviral agent were certainly present. In Comparative Example 11, which used only CPC, the ratio of N did not increase compared to the control, and it can be seen that the antibacterial and antiviral agent was not retained under conditions in which GO was not present. Furthermore, it was found that by using GO and the antibacterial and antiviral agent in combination, a sufficient amount of the antibacterial and antiviral agent could be maintained even if it was stored in water for one month.
[0135] As for the SEM measurements, from Figs. 16 to 19, the presence of GO can be confirmed, and it is clear that it is a single layer to several layers.
[0136] The results in Figure 34 show that the antibacterial and antiviral composite, which has a structure in which the substrate, carbon material, and antibacterial and antiviral agent are layered in this order, exhibited high antibacterial activity even after being submerged in water for one week, and although the antibacterial activity decreased after one month, it could be restored by applying the antibacterial agent again. This makes it possible to provide an antibacterial and antiviral composite that is highly water resistant and easy to restore.
Claims
1. The substrate, the carbon material, and the antibacterial and antiviral agent are laminated in this order. the carbon material is graphene oxide or reduced graphene oxide; An antibacterial / antiviral complex, characterized in that the antibacterial / antiviral agent has a cationic structure.
2. The antibacterial and antiviral complex according to claim 1, characterized in that the antibacterial and antiviral agent has at least one selected from the group consisting of a quaternary nitrogen cation-containing group and a primary to tertiary amino group.
3. 3. The antibacterial and antiviral complex according to claim 2, wherein the quaternary nitrogen cation-containing group is at least one selected from the group consisting of a quaternary ammonium group, an iminium group, and a pyridinium group.
4. The antibacterial and antiviral composite according to any one of claims 1 to 3, characterized in that the substrate is at least one selected from the group consisting of metal, glass, fiber, collagen, cellulose, resin, ceramic, enamel and dentin.
5. 5. The antibacterial and antiviral composite according to any one of claims 1 to 4, characterized in that the antibacterial and antiviral composite has an average number of layers of the carbon material of 10 or less.
6. A method for applying an antibacterial and / or antiviral coating to a substrate, the method comprising: forming a film of a carbon material on the substrate; and compounding an antibacterial and / or antiviral agent with the carbon material on the substrate obtained in the film-forming step; the carbon material is graphene oxide or reduced graphene oxide; The antibacterial and antiviral coating method is characterized in that the antibacterial and antiviral agent has a cationic structure.
7. 7. The antibacterial and antiviral coating method according to claim 6, wherein a carbon material composition having a carbon material concentration of 0.001 to 10 mass % is used in the film forming step.
8. A method for producing an antibacterial and antiviral composite, the method comprising: forming a film of a carbon material on a substrate; and compounding an antibacterial and antiviral agent with the carbon material on the substrate obtained in the film-forming step, the carbon material is graphene oxide or reduced graphene oxide; A method for producing an antibacterial / antiviral complex, wherein the antibacterial / antiviral agent has a cationic structure.
9. 9. The method for producing an antibacterial and antiviral composite according to claim 8, wherein a carbon material composition having a carbon material concentration of 0.001 to 10 mass % is used in the film-forming step.
10. A set for producing an antibacterial and antiviral composite, the set comprising a carbon material or a carbon material composition and an antibacterial and antiviral agent or an antibacterial and antiviral agent composition, the carbon material is graphene oxide or reduced graphene oxide; A set for producing an antibacterial / antiviral complex, characterized in that the antibacterial / antiviral agent has a cationic structure.
Citation Information
Patent Citations
Compound antibacterial gel, preparation method thereof and applications thereof
CN103598179B
Antibacterial mask and preparation method thereof
CN111096499A
Antibiotic PVC membrane
CN206913845U
Medical switching optical fiber
CN211348706U
JP1971022116B1
